Ensysce Biosciences, Inc. (ENSC) AI Stock Analysis

Ensysce Biosciences, Inc. is a clinical-stage pharmaceutical company focused on developing prescription drugs for severe pain management while reducing opioid addiction, abuse, and overdose in the United States. Its technology includes the Trypsin Activated Abuse Protection (TAAP) and Multi-Pill Abuse Resistance (MPAR) platforms. The lead product candidate is PF614, an oxycodone prodrug in Phase II clinical trials for acute and chronic pain. The company is also evaluating PF614-MPAR for overdose protection, along with PF329 for hydromorphone delivery, PF8001 and PF8026 for ADHD abuse prevention, and PF26810 for opioid use disorder.

Revenue grew at a 5-year CAGR of 5.2% from FY2020 to FY2025. Annual revenue was $3.5M in FY2021, $2.5M in FY2022, and $2.2M in FY2023 before rising to $5.2M in FY2024. In FY2025, revenue fell 2.8% to $5.1M, accompanied by a gross margin of -104.8%, an operating margin of -202.1%, and net income of -$10.2M. Diluted EPS was -$4.22 in FY2025 following -$13.40 in FY2024. Over the trailing twelve months ended June 30, 2026, revenue stood at $4.5M with an operating margin of -221.3%. For the latest quarter ended June 30, 2026, quarterly revenue fell 15.1% year-over-year.

As of June 30, 2026, Ensysce Biosciences held $676,704 in cash and short-term investments and $196,842 in total debt, yielding net cash of $479,862. Shareholders' equity was -$781,697 alongside total assets of $3.0M, resulting in a current ratio of 0.70. For FY2025, operating cash flow was -$7.8M and free cash flow was -$7.9M. Cash use included $123,643 in capital expenditures, while the company raised capital through $9.8M in share issuances, contributing to a 5-year share count change of 12883.7%.

At a last close of $0.52 on October 16, 2026, Ensysce Biosciences had a market capitalization of $10.1M and an enterprise value of $7.6M. The stock trades at a price-to-sales ratio of 2.2x and a forward P/E of 0.9x, compared to medians of 4.1x and 17.3x, respectively, for its US-listed Healthcare peers. Its price-to-book ratio is 0.9x. Over the past year, ENSC dropped 79.8%, while the S&P 500 (SPY) returned 16.8%. Over five years, ENSC declined 100.0% versus an 83.0% gain for SPY.

One analyst provides estimates for the next fiscal year. The mean price target is $8.25, representing a 1492.7% premium over the last close of $0.52. For the fiscal year ending December 31, 2026, consensus estimates project revenue of $4.6M and an EPS of -$1.09. For the next fiscal year, estimates project revenue of $0 and an EPS of -$0.05. The company beat EPS estimates in 3 of the last 4 quarters. The next earnings date is November 13, 2026.

This page is an AI-written research summary of Ensysce Biosciences, Inc. (ENSC). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: ENSC income statement, ENSC balance sheet, ENSC key metrics, ENSC analyst forecast, ENSC chart. See the ENSC stock overview for the latest quote and news.